BellBrook Labs’ Transcreener® ADP Assay is on Target for…

The ubiquitin-selective chaperone, p97, is emerging as an exciting new therapeutic target for diverse diseases and pathologies, however its low intrinsic ATPase activity has made it difficult to adapt...

(PRWeb April 20, 2012)

Read the full story at

Comments are closed.

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: